Condition: Vitiligo, Generalized · Sponsor: South Valley University
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
This description comes directly from the study's public registry record.
Eman A Osman, bachelor · +20 1127052748 · em.ea01127@gmail.com
Hassan mo farid, bachelor · +201040435051 · dr.hassanfarid96@gmail.com
Always discuss trial participation with your own doctor first.
| Qena university hospital, Qena faculty of medicine | Qina, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06768840